Pancreatic Cancer Research

ResearcherNational Yang Ming Chiao Tung UniversityActive in the last 2 years

Wen‐Chun Hung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4860-5415; OpenAlex author ID A5087031696, A5102328796. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 5 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 15

  1. Dual inhibition of tumor cells and tumor-associated neutrophils by anti-CXCR2 antibodies suppresses tumor growth and augments immunotherapy efficacy in ARID1A-… Last author DOI 10.1007/s00262-026-04498-6↗
  2. Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition. Last author DOI 10.1002/ctm2.70394↗
  3. Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination. Co-author PMID 37693128↗
  4. The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy. Last author DOI 10.3390/biomedicines10040926↗
  5. Semaphorin 6C Suppresses Proliferation of Pancreatic Cancer Cells via Inhibition of the AKT/GSK3/β-Catenin/Cyclin D1 Pathway. Co-author DOI 10.3390/ijms23052608↗
  6. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer. Co-author DOI 10.1186/s12943-019-1023-1↗
  7. Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer. Last author DOI 10.1186/s13045-019-0769-7↗
  8. Deciphering The Potential Role of Hox Genes in Pancreatic Cancer. Last author DOI 10.3390/cancers11050734↗
  9. Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. Co-author DOI 10.3390/jcm8060903↗
  10. β-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer. Last author DOI 10.7150/thno.28201↗
  11. Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase ABCG2 Expression. Last author DOI 10.3390/cancers11010008↗
  12. Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer. Co-author PMID 30323973↗
  13. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Last author DOI 10.18632/oncotarget.11256↗
  14. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. Last author DOI 10.18632/oncotarget.3613↗
  15. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1186/1471-2407-14-181↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li‐Tzong Chen · 12 shared papers, 2016–2026 · strength 2.07
  2. Yan‐Shen Shan · 8 shared papers, 2016–2025 · strength 1.16
  3. Tzu‐Lei Kuo · 5 shared papers, 2014–2026 · strength 1.02
  4. Yu‐Hsuan Hung · 4 shared papers, 2019–2023 · strength 0.73
  5. Ya‐Chin Hou · 3 shared papers, 2022–2025 · strength 0.68
  6. Mei‐Ren Pan · 5 shared papers, 2016–2019 · strength 0.46
  7. Kuang‐Hung Cheng · 4 shared papers, 2014–2019 · strength 0.41
  8. Ming‐Chuan Hsu · 4 shared papers, 2016–2019 · strength 0.38
  9. Yung‐Yeh Su · 2 shared papers, 2022–2023 · strength 0.35
  10. Ching‐Chieh Weng · 2 shared papers, 2014–2019 · strength 0.15
  11. Mei-Jen Hsieh · 1 shared paper, 2019 · strength 0.10
  12. Yu‐Chun Lin · 1 shared paper, 2019 · strength 0.10
  13. Hsiu-Mei Chen · 1 shared paper, 2015 · strength 0.08
  14. Yufeng Tian · 1 shared paper, 2018 · strength 0.08
  15. Hui‐Ching Wang · 1 shared paper, 2018 · strength 0.08
  16. Kung‐Kai Kuo · 1 shared paper, 2014 · strength 0.04
  17. Yu-Wen Chen · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.